Article: 2-[125I]iodomelatonin-binding sites in the human kidney and the effect of guanosine 5'-0-(3-thiotriphosphate)

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
Title2-[125I]iodomelatonin-binding sites in the human kidney and the effect of guanosine 5'-0-(3-thiotriphosphate)
AuthorsSong, Y1 2
Tam, PC3
Poon, AMS1
Brown, GM2
Pang, SF1 2
Issue Date1995
PublisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org
CitationJournal of Clinical Endocrinology and Metabolism, 1995, v. 80 n. 5, p. 1560-1565 [How to Cite?]
AbstractPutative melatonin receptors in normal kidney cortical tissues of patients with transitional cell carcinoma or renal cell carcinoma were characterized using a melatonin agonist, 2-[125I]iodomelatonin, as the radioligand. 2-[125I]Iodomelatonin-binding sites in the human kidney were stable, saturable, reversible, and of high affinity. The binding affinity was 15.2 +/- 2.5 pmol/L, and the binding density was 1.79 +/- 0.19 fmol/mg protein. The unity of the Hill coefficients and linearity of the Scatchard plots suggested that 2-[125I]iodomelatonin was bound to a single class of binding sites. Pharmacological characterization showed that these binding sites were highly specific to 2-iodomelatonin, melatonin, 6-hydroxymelatonin, and 6-chloromelatonin. Guanosine 5'-O-(3-thiotriphosphate) decreased the binding affinity and density of 2-[125I]iodomelatonin-binding sites in the kidney, suggesting that these binding sites are coupled to a G-protein. The characterization of 2-[125I]iodomelatonin-binding sites in normal kidney tissues taken from patients with transitional cell carcinoma or renal cell carcinoma suggests the existence of 2-[125I]iodomelatonin-binding sites in the human kidney cortex, which is in line with the findings of 2-[125I]iodomelatonin-binding sites in kidneys of other mammals and birds. The implication of a direct melatonin action on renal function in the human is proposed.
ISSN0021-972X
2011 Impact Factor: 5.967
2011 SCImago Journal Rankings: 0.579
ISI Accession Number IDWOS:A1995QW61100020
DC Field
Value
dc.contributor.authorSong, Y
dc.contributor.authorTam, PC
dc.contributor.authorPoon, AMS
dc.contributor.authorBrown, GM
dc.contributor.authorPang, SF
dc.date.accessioned2008-06-12T06:38:43Z
dc.date.available2008-06-12T06:38:43Z
dc.date.issued1995
dc.description.abstractPutative melatonin receptors in normal kidney cortical tissues of patients with transitional cell carcinoma or renal cell carcinoma were characterized using a melatonin agonist, 2-[125I]iodomelatonin, as the radioligand. 2-[125I]Iodomelatonin-binding sites in the human kidney were stable, saturable, reversible, and of high affinity. The binding affinity was 15.2 +/- 2.5 pmol/L, and the binding density was 1.79 +/- 0.19 fmol/mg protein. The unity of the Hill coefficients and linearity of the Scatchard plots suggested that 2-[125I]iodomelatonin was bound to a single class of binding sites. Pharmacological characterization showed that these binding sites were highly specific to 2-iodomelatonin, melatonin, 6-hydroxymelatonin, and 6-chloromelatonin. Guanosine 5'-O-(3-thiotriphosphate) decreased the binding affinity and density of 2-[125I]iodomelatonin-binding sites in the kidney, suggesting that these binding sites are coupled to a G-protein. The characterization of 2-[125I]iodomelatonin-binding sites in normal kidney tissues taken from patients with transitional cell carcinoma or renal cell carcinoma suggests the existence of 2-[125I]iodomelatonin-binding sites in the human kidney cortex, which is in line with the findings of 2-[125I]iodomelatonin-binding sites in kidneys of other mammals and birds. The implication of a direct melatonin action on renal function in the human is proposed.
dc.description.naturepublished_or_final_version
dc.format.extent418 bytes
dc.format.mimetypetext/html
dc.identifier.citationJournal of Clinical Endocrinology and Metabolism, 1995, v. 80 n. 5, p. 1560-1565 [How to Cite?]
dc.identifier.hkuros2701
dc.identifier.isiWOS:A1995QW61100020
dc.identifier.issn0021-972X
2011 Impact Factor: 5.967
2011 SCImago Journal Rankings: 0.579
dc.identifier.openurl
dc.identifier.pmid7745000
dc.identifier.scopuseid_2-s2.0-0028989283
dc.identifier.urihttp://hdl.handle.net/10722/49294
dc.languageeng
dc.publisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org
dc.rightsJournal of Clinical Endocrinology and Metabolism. Copyright © The Endocrine Society.
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
dc.subject.meshGuanosine 5'-O-(3-thiotriphosphate) - pharmacology
dc.subject.meshKidney cortex - metabolism
dc.subject.meshMelatonin - analogs & derivatives - metabolism - pharmacokinetics
dc.subject.meshCarcinoma, renal cell - metabolism
dc.subject.meshCarcinoma, transitional cell - metabolism
dc.title2-[125I]iodomelatonin-binding sites in the human kidney and the effect of guanosine 5'-0-(3-thiotriphosphate)
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. Centre for Addiction and Mental Health
  3. Queen Mary Hospital Hong Kong